Osteosarcoma Institute: Various competitive LOI’s

Correlative Science

Seeking to generate data from clinical trials aimed at improving event free survival of recurrent and metastatic osteosarcoma patients.

Funding: $200K–$500K over two years (indirect costs not to exceed 10% of the requested project budget).

Preclinical/Translational

A translational imperative for the OSI is to cultivate and support a research agenda that will identify biological dependencies in the disease that can be targeted in patients. This research agenda will ideally include the use of novel laboratory approaches and bioinformatic tools applied to osteosarcoma cells, a diversity of in vivo models across species and human patient samples.

Funding: $500K over two years (indirect costs not to exceed 10% of the requested project budget).

High-Risk/High-Impact

The aim of this grant program is to place less emphasis on preliminary data to encourage projects exploring bold innovations that may fall within any stage of the drug development path, and that seek to deliver curative outcomes to patients with osteosarcoma.

Funding: $25K–$125K over one year (indirect costs not to exceed 10% of the requested project budget).

Clinical Trials

The primary objective of proposed Phase I/II or Phase II clinical trials in relapsed/refractory osteosarcoma should be to improve event free survival (EFS) at 4 months beyond historical rates known to be in the range of 12% for patients with unresectable disease.

Funding: Up to $80K over two to three years (indirect costs not to exceed 10% of the project budget requested).

https://osinst.org/researchers/#grants